Table 1 Patient Demographics and Characteristics
|  | Mannitol (n = 63) | Saline only (n = 47) |
|---|---|---|
Sex | ||
Male, n (%) | 40 (63.5) | 24 (51.1) |
Female, n (%) | 23 (36.5) | 23 (48.9) |
Age, median 44.5 yo | ||
  ≥ 40 years old (n = 71; 64.5) | 32 (51.6) | 39 (81.2) |
  < 40 years old (n = 39; 35.5) | 31 (48.4) | 8 (18.8) |
Type of cancer | ||
 Nasopharynx (n = 61; 55.5%) | 41 (66.1) | 20 (41.7) |
 Head and neck cancer other than nasopharyngeal (n = 14; 12.7%) | 8 (12.9) | 6 (12.5) |
 Osteosarcoma (n = 11; 10%) | 8 (12.9) | 3 (6.2) |
 Breast (n = 3; 2.7%) | 0 (0) | 3 (6.2) |
 Ovary (n = 4; 3.6%) | 0 (0) | 4 (8.5) |
 Others (n = 17; 15.5%) | 5 8.0) | 12 (25.1) |
Anticancer drugs | ||
 5FU (n = 49; 44.5%) | 40 (64.5) | 9 (18.8) |
 Docetaxel (n = 20; 18.2%) | 10 (16.1) | 9 (18.8) |
 Paclitaxel (n = 10; 9.1%) | 2 (3.2) | 8 (16.7) |
 Doxorubicin (n = 9; 8.2%) | 7 (11.3) | 3 (6.2) |
 Nimotuzumab (n = 7; 6.45%) | 0 (0) | 7 (14.6) |
 Etoposide (n = 5; 4.5%) | 1 (1.6) | 4 (8.3) |
 Others (n = 10; 9%) | 2 (3.2) | 8 (16.7) |
Dose of Cisplatin (mg/m2) | ||
 100 (n = 74; 67.3%) | 53(84.1) | 21(44.7) |
 80 (n = 7; 6.4%) | 2(3.2) | 5(10.6) |
 75 (n = 29; 6.4) | 8(12.7) | 21 (44.7) |
Cumulative dose of cisplatin before the current chemotherapy (mg/m2) | ||
  ≤ 100, n (%) | 52 (83.9) | 38 (79.2) |
 101–200, n (%) | 7 (11.3) | 9 (18.8) |
 201–300, n (%) | 2 (3.2) | 1 (2.1) |
  > 300, n (%) | 1 (1.6) | 0 |
Chemotherapy Cycle | ||
 1st (n = 69, 62.7%) | 34 (54.0) | 35 (74.5) |
 2nd (n = 22, 20%) | 17 (27.0) | 5 (10.6) |
 3rd (n = 3, 14%) | 8 (12.7) | 6 (12.8) |
 4th (n = 5, 4.5%) | 4 (6.3) | 1 (2.1) |
Diabetes Mellitus (n = 3 [2.7]) | 0 (0) | 3 (6.4) |
Hypertension (n = 8 [7.3]) | 4 (6.3) | 4 (8.5) |
Concomitant Radiotherapy | ||
 No (n = 91 [83.5]) | 55 (60.4) | 36 (39.6) |